Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group
urpose: The medium-risk (IR) prostate cancer (PCa) are a heterogeneous group in terms of prognosis. For unfavorable or favorable IR PCa treated with radiotherapy, the remnants of the optimal strategy to be defined. In routine practice, doctor’s decision to propose hormonal therapy (HT) is controversial. PROACT survey aims to evaluate patterns and preferences of daily practice in France at this IR population.
Materials and Methods: A questionnaire was distributed to member web 91 French radiotherapy centers of the Groupe d’Etude des Tumeurs Uro-Genitales (GETUG). The questionnaire included four sections on: (i) specialists who prescribe treatment and multidisciplinary decision (MTD) validation; (Ii) the definition of patient subsets IR; (Iii) the parameters of radiotherapy; (Iv) regarding the practice patterns of cardiovascular (CV) and (iv) a metabolic evaluation. Descriptive presentation of the results is used.
Results: Among the 82 responses (90% of the centers), HT schedule and irradiation techniques validated by a particular board meeting in 54% and 45% of the center, respectively. Three-quarters (76%) of centers identify a subset of patients with IR to specific strategies. The majority of the center considers PSA> 15 (77%) and / or Gleason 7 (4 + 3) (87%) for the definition of IR unfavorable. Overall, 41% of the center is carried out systematically evaluate CV before HT prescription while 61% only consider CV history / status in defining the type of HT. LHRH agonists is often prescribed in both favorable (70%) and unfavorable (98%) patients with IR. Finally, weight loss (80%), metabolic profile (70%) and CV status (77%) of patients considered for follow-up under HT.
Conclusion: To the best of our knowledge, this is the first survey on practices in IR PCa HT. PROACT survey showed that three-quarters of respondents identified a subset of IR-patients in adjusting therapy. CV status of patients considered in guiding decisions HT, duration and type of .
Two professions against two killer diseases: reason, organizations, and the initial experience cardio-oncology services
Background: Cardiovascular disease (CV) is the most common factor affecting the prognosis in cancer patients. Cardio-oncology (CO) service has been developed to solve this problem. The lack of results regarding patient demographics and clinical findings applicable and available data is limited to the services CO evaluate patients undergoing chemotherapy only.
Purpose: To demonstrate initial experience CO service was conducted in a tertiary oncology centers. Methods: CO Service is designed to include two major domains: general and consulting CO electrotherapy. Patients who are referred to a collection service CO with basic demographics, type of cancer, the reason for referral, cardiac evaluation, and initial clinical results were included in this observational study.
Results: All cancer patients referred to our CO service between March 2016 and December 2019 included in this study. A total of 2,762 (77% female) patients at a mean (SD) age of 62 (12) years referenced (63% on the basis of hospitalization) for public consultation.
The most frequent diagnosis was breast cancer (66%). In 18% of patients, the reason for referral to services CO is the treatment of cancer-related complications CV. A total of 652 patients (515 patients with cardiac implantable electronic device (CIED) eligible for radiotherapy (RT), 48 patients with diagnosed CIEDs by magnetic resonance imaging (MRI), and 89 patients with cancer treated with surgery CIED) were evaluated by a team CO- CIED. During the 5872 session of the RT total, two dangerous interactions and no other complications during MRI and surgery were recorded.
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group
Diet Association Quality With Survival Among People With Metastatic Colorectal Cancer at the Cancer and Leukemia Group B and the Southwest Oncology 80 405 Experiment
Importance: Diet has been associated with survival in patients with stage I to III colorectal cancer, but the data in patients with metastatic colorectal cancer are limited.
Objective: To examine the relationship between diet quality and overall survival among individuals with metastatic colorectal cancer.
Design, setting, and participants: This study is a prospective cohort study of patients with metastatic colorectal cancer enrolled in the Cancer and Leukemia Group B (Alliance) and the Southwest Oncology Group 80 405 trials between 27 October 2005 and 29 February 2012, and followed up through January 2018 ,
Exposure: Participants completed a validated food frequency questionnaire within 4 weeks after starting first-line treatment for metastatic colorectal cancer. Diet categorized according to the Alternative Healthy Eating Index (AHEI), Alternative Mediterranean Diet (AMED) score, diet Approaches to Stop Hypertension (DASH) score, and Western and prudent dietary pattern derived using principal component analysis. Participants were classified into sex-specific quintiles.
The main results and measures: multivariable hazard ratio (HR) and 95% CI for overall survival.
Description: Quantitative sandwich ELISA kit for measuring Mouse Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitative sandwich ELISA kit for measuring Mouse Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Quantitativesandwich ELISA kit for measuring Rat Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Rat Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human Vascuoar endothelial cell growth factor receptor 2,VEGFR-2/Flk-1 ELISA kit
Description: Quantitative sandwich ELISA kit for measuring Human Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitative sandwich ELISA kit for measuring Human Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human Vascuoar endothelial cell growth factor receptor 2(VEGFR-2/Flk-1)ELISA Kit
Description: Quantitative sandwich ELISA for measuring Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)
Description: Quantitative sandwich ELISA for measuring Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)
Description: Quantitative sandwich ELISA for measuring Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)
Description: Quantitative sandwich ELISA for measuring Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)
Description: Quantitative sandwich ELISA for measuring Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)
Description: Quantitative sandwich ELISA for measuring Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Vascular endothelial cell growth factor receptor 2,VEGFR-2/Flk-1
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Vascular endothelial cell growth factor receptor 2,VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates and other biological fluids.
Results: In a cohort study of 1284 individuals with metastatic colorectal cancer, the median age was 59 (interquartile range [IQR]: 51-68) years, body mass index, the average was 27.2 (IQR, 24.1 to 31, 4), 521 (41%) were women, and in 1102 (86%) were white. There are 1100 deaths during a median follow-up of 73 months (IQR, 64-87 months). We observed an inverse relationship between a score of AMED and the risk of death (HR quintile 5 vs first quintile, 0.83; 95% CI, 0.67 to 1.04; P = 0.04 for trend), but the estimate is not statistically significant point , None of the other diet or pattern values associated with overall survival.
Conclusion and relevance: In this prospective analysis of patients with metastatic colorectal cancer, diet quality were assessed at start of first-line treatment for metastatic disease was not associated with overall survival.
